ICML 2023 | 15-year follow-up of SWOG-S0016: achieving a functional cure in a subset of patients with FL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, shares the 15-year follow-up results from the SWOG-S0016 study (NCT00006721) comparing the safety and efficacy of R-CHOP with CHOP-RIT (CHOP followed by consolidation with iodine-133-tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma (FL). The 15-year overall survival (OS) and progression-free survival (PFS) for the entire cohort were 70% and 40% respectively. In addition, the rate of progression decreased over time, indicating the possibility of achieving a functional cure in a subset of patients with FL. These results provide a benchmark for studies utilizing novel agents in the frontline setting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
